Mary Bamimore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mary Bamimore has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Kumar Gupta
Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario
9 shared publications - Mesbah Talukder
School of Pharmacy BRAC University Dhaka Bangladesh
5 shared publications - Maanasa Venkataraman
Mediprobe Research Inc. , London, ON , Canada
2 shared publications Avantika Mann
Mediprobe Research Inc. London Ontario Canada
1 shared publication- Deanna C. Hall
Mediprobe Research Inc. London Ontario Canada
1 shared publication Greg Williams
Farjo Hair Institute London UK
1 shared publication
Latest Publications
- Open Access
- 15 July 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (1) , 108-118
Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System
Background: The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation. These AEs are controversial and often lack assessment of contributing risk factors. We analyzed FDA Adverse Event Reporting System (FAERS) data to explore finasteride's administration route and PFS‐like AEs. Methods: Using the information component (IC) method for disproportionality analyses, we assessed signals for 13 PFS‐related AEs with topical and oral finasteride and dutasteride across two periods: 2006–2011 (pre‐PFS reporting) and 2019–2024 (post‐PFS reporting). These periods reflect times before and after formal PFS reporting in 2012. Eight analyses per AE were conducted based on agent, route, and era. Results: Fewer signals for PFS‐like AEs were detected with topical finasteride compared to oral finasteride in both eras. No signals were found for topical dutasteride, possibly because its use is very limited. Many reported AEs, such as erectile dysfunction and depression, may be influenced by age, stress, or comorbidities. Conclusions: Signals for PFS‐like AEs were detected with topical finasteride, but were less frequent than with oral finasteride. The high prevalence of these AEs in the general population and the influence of confounding factors, such as psychological stress or nocebo effects, combined with the lack of genotyping, hormonal assessments, or family history data in most reports, suggest caution in attributing causality to finasteride. Topical finasteride may pose a lower risk, but robust evidence is needed to clarify its safety profile.
- 15 July 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (1) , 108-118
Open AccessIs the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System
Background: The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation. These AEs are controversial and often lack assessment of contributing risk factors. We analyzed FDA Adverse Event Reporting System (FAERS) data to explore finasteride's administration route and PFS‐like AEs. Methods: Using the information component (IC) method for disproportionality analyses, we assessed signals for 13 PFS‐related AEs with topical and oral finasteride and dutasteride across two periods: 2006–2011 (pre‐PFS reporting) and 2019–2024 (post‐PFS reporting). These periods reflect times before and after formal PFS reporting in 2012. Eight analyses per AE were conducted based on agent, route, and era. Results: Fewer signals for PFS‐like AEs were detected with topical finasteride compared to oral finasteride in both eras. No signals were found for topical dutasteride, possibly because its use is very limited. Many reported AEs, such as erectile dysfunction and depression, may be influenced by age, stress, or comorbidities. Conclusions: Signals for PFS‐like AEs were detected with topical finasteride, but were less frequent than with oral finasteride. The high prevalence of these AEs in the general population and the influence of confounding factors, such as psychological stress or nocebo effects, combined with the lack of genotyping, hormonal assessments, or family history data in most reports, suggest caution in attributing causality to finasteride. Topical finasteride may pose a lower risk, but robust evidence is needed to clarify its safety profile.
- 25 June 2025
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
The comparative effectiveness of prescription and selected alternative therapies for pattern hair loss: protocol for a multiple treatment comparison meta-analysis
INPLASY202560102 The comparative effectiveness of prescription and selected alternative therapies for pattern hair loss: protocol for a multiple treatment comparison meta-analysis Keywords: total h…
- 25 June 2025
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
The comparative effectiveness of prescription and selected alternative therapies for pattern hair loss: protocol for a multiple treatment comparison meta-analysis
INPLASY202560102 The comparative effectiveness of prescription and selected alternative therapies for pattern hair loss: protocol for a multiple treatment comparison meta-analysis Keywords: total h…
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 1529-1539
Assessing Quality of Life in Patients with Epidermolysis Bullosa in the Saudi Population: Validation of the QOLEB Questionnaire
Background: Epidermolysis bullosa (EB) is a rare condition where skin easily blisters. Using an Arabic-translated Quality of Life in Epidermolysis bullosa (QOLEB) questionnaire, we evaluated quality of life across persons with EB in Kingdom of Saudi Arabia. Methods: Respondents were selected through nonprobability convenience sampling. Data were collected using a pre-validated questionnaire. We statistically compared response data across the four EB phenotypes using the Kruskal–Wallis test. Validity was assessed through confirmatory factor analysis and Cronbach’s alpha was used to evaluate reliability with results 0.88. Results: The study included 91 participants with Epidermolysis Bullosa (EB), comprising 60.4% of them were males. Adults and adolescents constituted 61.5% of the study sample. Children with EB faced more bathing challenges, with 64.3% always needing assistance compared to 31.4% of adults/adolescents. Writing adaptations varied significantly (p=0.03), with children exploring alternatives like typing, while adults primarily struggled to hold a pen. Conclusion: Our findings underscore the profound physical, psychological, and social burdens associated with this rare condition, emphasizing the critical need for multidisciplinary care approaches. Addressing gaps in public awareness, improving access to specialized care, and providing psychosocial support for patients and their families are essential steps toward enhancing quality of life.
- 1 June 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 1529-1539
Open AccessAssessing Quality of Life in Patients with Epidermolysis Bullosa in the Saudi Population: Validation of the QOLEB Questionnaire
Background: Epidermolysis bullosa (EB) is a rare condition where skin easily blisters. Using an Arabic-translated Quality of Life in Epidermolysis bullosa (QOLEB) questionnaire, we evaluated quality of life across persons with EB in Kingdom of Saudi Arabia. Methods: Respondents were selected through nonprobability convenience sampling. Data were collected using a pre-validated questionnaire. We statistically compared response data across the four EB phenotypes using the Kruskal–Wallis test. Validity was assessed through confirmatory factor analysis and Cronbach’s alpha was used to evaluate reliability with results 0.88. Results: The study included 91 participants with Epidermolysis Bullosa (EB), comprising 60.4% of them were males. Adults and adolescents constituted 61.5% of the study sample. Children with EB faced more bathing challenges, with 64.3% always needing assistance compared to 31.4% of adults/adolescents. Writing adaptations varied significantly (p=0.03), with children exploring alternatives like typing, while adults primarily struggled to hold a pen. Conclusion: Our findings underscore the profound physical, psychological, and social burdens associated with this rare condition, emphasizing the critical need for multidisciplinary care approaches. Addressing gaps in public awareness, improving access to specialized care, and providing psychosocial support for patients and their families are essential steps toward enhancing quality of life.
- Open Access
- 13 March 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (3) , e70102
Finasteride Use: Evaluation of Depression and Suicide Risk
Background: Oral finasteride 1 mg/day is indicated for androgenetic alopecia (AGA), while 5 mg/day is for benign prostatic hyperplasia (BPH). Oral finasteride has been linked with depression and suicide; however, a causal association is uncertain. The so‐called post‐finasteride syndrome (PFS) refers to a “cluster” of side effects experienced by some men (i.e., cis men) after taking oral finasteride.Aims: The objective of the current study was to evaluate the association of depression and suicide with oral finasteride in males, using data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS). As a secondary objective, we conducted disproportionality analyses of FAERS data to assess whether oral dutasteride use was linked to psychological symptoms related to depression and suicidality.Methods: We conducted disproportionality analyses for 5 AEs using MedDRA terms. Associations were metricized with the reporting odds ratio (ROR) across 3 time periods, namely, 2006–2011, 2013–2018, and 2019–2023.Results: No significant AEs/signals were detected with oral finasteride from 2006 to 2011 for any of the 5 AEs (completed suicide, depression suicidal, suicidal behavior, suicidal ideation, attempted suicide). Signals were detected for some AEs during 2013–2018 and 2019–2023. For example, there was a greater likelihood of reporting suicidal ideations in individuals taking oral finasteride during 2013–2018 (ROR = 2.8, p < 0.05) and 2019–2023 (ROR = 5.0, p < 0.05). In contrast, no signals were detected with oral dutasteride during 2006–2011, 2013–2018, and 2019–2023.Conclusion: The study found no significant correlation between oral finasteride and depression/suicide reports from 2006 to 2011 but noted a significant number of such reports in 2013–2018 and 2019–2023. This increase may be linked to heightened awareness of AEs following the recognition of so‐called PFS in 2012.
- 13 March 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (3) , e70102
Open AccessFinasteride Use: Evaluation of Depression and Suicide Risk
Background: Oral finasteride 1 mg/day is indicated for androgenetic alopecia (AGA), while 5 mg/day is for benign prostatic hyperplasia (BPH). Oral finasteride has been linked with depression and suicide; however, a causal association is uncertain. The so‐called post‐finasteride syndrome (PFS) refers to a “cluster” of side effects experienced by some men (i.e., cis men) after taking oral finasteride.Aims: The objective of the current study was to evaluate the association of depression and suicide with oral finasteride in males, using data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS). As a secondary objective, we conducted disproportionality analyses of FAERS data to assess whether oral dutasteride use was linked to psychological symptoms related to depression and suicidality.Methods: We conducted disproportionality analyses for 5 AEs using MedDRA terms. Associations were metricized with the reporting odds ratio (ROR) across 3 time periods, namely, 2006–2011, 2013–2018, and 2019–2023.Results: No significant AEs/signals were detected with oral finasteride from 2006 to 2011 for any of the 5 AEs (completed suicide, depression suicidal, suicidal behavior, suicidal ideation, attempted suicide). Signals were detected for some AEs during 2013–2018 and 2019–2023. For example, there was a greater likelihood of reporting suicidal ideations in individuals taking oral finasteride during 2013–2018 (ROR = 2.8, p < 0.05) and 2019–2023 (ROR = 5.0, p < 0.05). In contrast, no signals were detected with oral dutasteride during 2006–2011, 2013–2018, and 2019–2023.Conclusion: The study found no significant correlation between oral finasteride and depression/suicide reports from 2006 to 2011 but noted a significant number of such reports in 2013–2018 and 2019–2023. This increase may be linked to heightened awareness of AEs following the recognition of so‐called PFS in 2012.
- Open Access
Global prevalence of onychomycosis in general and special populations: An updated perspective
Background: Onychomycosis is a chronic nail disorder commonly seen by healthcare providers; toenail involvement in particular presents a treatment challenge.Objective: To provide an updated estimate on the prevalence of toenail onychomycosis.Methods: We conducted a literature search using PubMed, Embase and Web of Science. Studies reporting mycology‐confirmed diagnoses were included and stratified into (a) populations‐based studies, and studies that included (b) clinically un‐suspected and (c) clinically suspected patients.Results: A total of 108 studies were included. Based on studies that examined clinically un‐suspected patients (i.e., with or without clinical features suggestive of onychomycosis), the pooled prevalence rate of toenail onychomycosis caused by dermatophytes was 4% (95% CI: 3–5) among the general population; special populations with a heightened risk include knee osteoarthritis patients (RR: 14.6 [95% CI: 13.0–16.5]), chronic venous disease patients (RR: 5.6 [95% CI: 3.7–8.1]), renal transplant patients (RR: 4.7 [95% CI: 3.3–6.5]), geriatric patients (RR: 4.7 [95% CI: 4.4–4.9]), HIV‐positive patients (RR: 3.7 [95% CI: 2.9–4.7]), lupus erythematosus patients (RR: 3.1 [95% CI: 1.2–6.3]), diabetic patients (RR: 2.8 [95% CI: 2.4–3.3]) and hemodialysis patients (RR: 2.8 [95% CI: 1.9–4.0]). The prevalence of onychomycosis in clinically suspected patients was significantly higher likely due to sampling bias. A high degree of variability was found in a limited number of population‐based studies indicating that certain pockets of the population may be more predisposed to onychomycosis. The diagnosis of non‐dermatophyte mould onychomycosis requires repeat sampling to rule out contaminants or commensal organisms; a significant difference was found between studies that performed single sampling versus repeat sampling. The advent of PCR diagnosis results in improved detection rates for dermatophytes compared to culture.Conclusion: Onychomycosis is an underrecognized healthcare burden. Further population‐based studies using standardized PCR methods are warranted.
Open AccessGlobal prevalence of onychomycosis in general and special populations: An updated perspective
Background: Onychomycosis is a chronic nail disorder commonly seen by healthcare providers; toenail involvement in particular presents a treatment challenge.Objective: To provide an updated estimate on the prevalence of toenail onychomycosis.Methods: We conducted a literature search using PubMed, Embase and Web of Science. Studies reporting mycology‐confirmed diagnoses were included and stratified into (a) populations‐based studies, and studies that included (b) clinically un‐suspected and (c) clinically suspected patients.Results: A total of 108 studies were included. Based on studies that examined clinically un‐suspected patients (i.e., with or without clinical features suggestive of onychomycosis), the pooled prevalence rate of toenail onychomycosis caused by dermatophytes was 4% (95% CI: 3–5) among the general population; special populations with a heightened risk include knee osteoarthritis patients (RR: 14.6 [95% CI: 13.0–16.5]), chronic venous disease patients (RR: 5.6 [95% CI: 3.7–8.1]), renal transplant patients (RR: 4.7 [95% CI: 3.3–6.5]), geriatric patients (RR: 4.7 [95% CI: 4.4–4.9]), HIV‐positive patients (RR: 3.7 [95% CI: 2.9–4.7]), lupus erythematosus patients (RR: 3.1 [95% CI: 1.2–6.3]), diabetic patients (RR: 2.8 [95% CI: 2.4–3.3]) and hemodialysis patients (RR: 2.8 [95% CI: 1.9–4.0]). The prevalence of onychomycosis in clinically suspected patients was significantly higher likely due to sampling bias. A high degree of variability was found in a limited number of population‐based studies indicating that certain pockets of the population may be more predisposed to onychomycosis. The diagnosis of non‐dermatophyte mould onychomycosis requires repeat sampling to rule out contaminants or commensal organisms; a significant difference was found between studies that performed single sampling versus repeat sampling. The advent of PCR diagnosis results in improved detection rates for dermatophytes compared to culture.Conclusion: Onychomycosis is an underrecognized healthcare burden. Further population‐based studies using standardized PCR methods are warranted.
- 30 May 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (1) , 12-22
Relative impact of traditional vs. newer oral antifungals for dermatophyte toenail onychomycosis: a network meta-analysis study
Background: There is a paucity of evidence regarding the relative therapeutic efficacy of treatments for onychomycosis. Objectives: We determined the relative efficacy of monotherapies for dermatophyte toenail onychomycosis with Bayesian network meta-analyses (NMAs). Methods: We searched PubMed, Scopus, EMBASE (Ovid) and CINAHL to identify studies that investigated the efficacy of monotherapy with oral antifungals for dermatophyte toenail onychomycosis in adults. In this paper, ‘regimen’ corresponds to a given agent and its dosage. The relative effects and surface under the cumulative ranking curve (SUCRA) values of the various regimens were estimated; evidence quality was assessed at the study level and across networks. Results: Data from 21 studies were used. Our two efficacy-related endpoints were: (i) mycological and (ii) complete cure at 1 year; safety-related endpoints were: (i) 1-year count of any adverse event (AE), (ii) 1-year odds of discontinuation due to any AE, (iii) 1-year odds of discontinuation due to liver issues. Thirty-five regimens were identified; the newer agents among these included posaconazole and oteseconazole. We compared the efficacy of newer regimens with traditional ones like ‘terbinafine 250 mg daily for 12 weeks’ and ‘itraconazole 200 mg daily for 12 weeks. We found that an agent’s dosage was associated with its efficacy; for example, the 1-year odds of mycological cure with terbinafine 250 mg daily for 24 weeks (SUCRA = 92.4%) were significantly greater than those of terbinafine 250 mg daily for 12 weeks (SUCRA = 66.3%) (odds ratio 2.62, 95% credible interval 1.57–4.54). We also found that booster regimens can increase efficacy. Our results showed that some triazoles could be more effective than terbinafine. Conclusions: This is the first NMA study of monotherapeutic antifungals – and their various dosages – for dermatophyte toenail onychomycosis. Our findings could provide guidance for the selection of the most appropriate antifungal agent, especially amid the growing concerns about terbinafine resistance.
- 30 May 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 189 (1) , 12-22
Relative impact of traditional vs. newer oral antifungals for dermatophyte toenail onychomycosis: a network meta-analysis study
Background: There is a paucity of evidence regarding the relative therapeutic efficacy of treatments for onychomycosis. Objectives: We determined the relative efficacy of monotherapies for dermatophyte toenail onychomycosis with Bayesian network meta-analyses (NMAs). Methods: We searched PubMed, Scopus, EMBASE (Ovid) and CINAHL to identify studies that investigated the efficacy of monotherapy with oral antifungals for dermatophyte toenail onychomycosis in adults. In this paper, ‘regimen’ corresponds to a given agent and its dosage. The relative effects and surface under the cumulative ranking curve (SUCRA) values of the various regimens were estimated; evidence quality was assessed at the study level and across networks. Results: Data from 21 studies were used. Our two efficacy-related endpoints were: (i) mycological and (ii) complete cure at 1 year; safety-related endpoints were: (i) 1-year count of any adverse event (AE), (ii) 1-year odds of discontinuation due to any AE, (iii) 1-year odds of discontinuation due to liver issues. Thirty-five regimens were identified; the newer agents among these included posaconazole and oteseconazole. We compared the efficacy of newer regimens with traditional ones like ‘terbinafine 250 mg daily for 12 weeks’ and ‘itraconazole 200 mg daily for 12 weeks. We found that an agent’s dosage was associated with its efficacy; for example, the 1-year odds of mycological cure with terbinafine 250 mg daily for 24 weeks (SUCRA = 92.4%) were significantly greater than those of terbinafine 250 mg daily for 12 weeks (SUCRA = 66.3%) (odds ratio 2.62, 95% credible interval 1.57–4.54). We also found that booster regimens can increase efficacy. Our results showed that some triazoles could be more effective than terbinafine. Conclusions: This is the first NMA study of monotherapeutic antifungals – and their various dosages – for dermatophyte toenail onychomycosis. Our findings could provide guidance for the selection of the most appropriate antifungal agent, especially amid the growing concerns about terbinafine resistance.
- Open Access
- 30 June 2022
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 8 (5) , 355-361
There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses
Background: Recently, low-dose oral minoxidil (LDOM) has entered the landscape of therapies for androgenetic alopecia (AGA). We determined whether using LDOM is associated with improving AGA in a dose-dependent manner; secondarily, we examined whether a dose-dependent association also exists for safety. Methods: Systematic searches were conducted in PubMed and Scopus to identify studies that would be eligible for our quantitative analyses; the logistics of our analyses was determined by the data we gathered. Results: Six studies were eligible for quantitative analyses; we conducted meta-regressions. We found that, for persons with AGA, increasing the dosage of LDOM by 1 mg/day was – after six months – significantly associated with an expected sex-adjusted increase in hair diameter (mean difference = 1.4 μm, p = 0.01), total hair density (mean difference = 47.1 hairs/cm2, p = 0.007), terminal hair density (mean difference = 9.1 hairs/cm2, p = 0.001), risk of hypertrichosis (mean difference = 17.9%, p = 0.006), and cardiovascular adverse events (mean difference = 4.8%, p = 0.004). Conclusions: Our study produced new evidence as our work is the first to show a positive dose-dependent association between the use of LDOM and change in hair diameter, hair density, risk of hypertrichosis, and cardiovascular adverse events for persons with AGA. Future randomized trials could produce causal evidence that would corroborate these dose-dependent associations.
- 30 June 2022
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 8 (5) , 355-361
Open AccessThere Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses
Background: Recently, low-dose oral minoxidil (LDOM) has entered the landscape of therapies for androgenetic alopecia (AGA). We determined whether using LDOM is associated with improving AGA in a dose-dependent manner; secondarily, we examined whether a dose-dependent association also exists for safety. Methods: Systematic searches were conducted in PubMed and Scopus to identify studies that would be eligible for our quantitative analyses; the logistics of our analyses was determined by the data we gathered. Results: Six studies were eligible for quantitative analyses; we conducted meta-regressions. We found that, for persons with AGA, increasing the dosage of LDOM by 1 mg/day was – after six months – significantly associated with an expected sex-adjusted increase in hair diameter (mean difference = 1.4 μm, p = 0.01), total hair density (mean difference = 47.1 hairs/cm2, p = 0.007), terminal hair density (mean difference = 9.1 hairs/cm2, p = 0.001), risk of hypertrichosis (mean difference = 17.9%, p = 0.006), and cardiovascular adverse events (mean difference = 4.8%, p = 0.004). Conclusions: Our study produced new evidence as our work is the first to show a positive dose-dependent association between the use of LDOM and change in hair diameter, hair density, risk of hypertrichosis, and cardiovascular adverse events for persons with AGA. Future randomized trials could produce causal evidence that would corroborate these dose-dependent associations.
- 9 July 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Evidence summary and critical appraisal of studies on the effectiveness and safety of non-conventional treatments for male androgenetic alopecia: a protocol for a systematic review
INPLASY202170027 Evidence summary and critical appraisal of studies on the effectiveness and safety of non-conventional treatments for male androgenetic alopecia: a protocol for a systematic review…
- 9 July 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Evidence summary and critical appraisal of studies on the effectiveness and safety of non-conventional treatments for male androgenetic alopecia: a protocol for a systematic review
INPLASY202170027 Evidence summary and critical appraisal of studies on the effectiveness and safety of non-conventional treatments for male androgenetic alopecia: a protocol for a systematic review…